Last reviewed · How we verify
PLD, cyclophosphamide, trastuzumab, paclitaxel
At a glance
| Generic name | PLD, cyclophosphamide, trastuzumab, paclitaxel |
|---|---|
| Also known as | pegylated liposomal doxorubicin (SCH 200746) |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC (PHASE2)
- PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer (PHASE2)
- Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: